Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:PKI Revvity (PKI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Revvity Stock (NYSE:PKI) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Revvity alerts:Sign Up Key Stats Today's Range N/A50-Day Range$115.24▼$137.1152-Week Range N/AVolume1.63 million shsAverage Volume851,117 shsMarket Capitalization$14.57 billionP/E Ratio15.01Dividend Yield0.24%Price Target$54.00Consensus RatingBuy Company OverviewRevvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.Read More… [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Revvity Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScorePKI MarketRank™: Revvity scored higher than 88% of companies evaluated by MarketBeat, and ranked 146th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRevvity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevvity has received no research coverage in the past 90 days.Read more about Revvity's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.71% Earnings GrowthEarnings for Revvity are expected to grow by 17.71% in the coming year, from $4.97 to $5.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.59.Price to Earnings Growth RatioRevvity has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PKI. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRevvity has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRevvity does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Revvity is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Revvity will have a dividend payout ratio of 4.79% next year. This indicates that Revvity will be able to sustain or increase its dividend.Read more about Revvity's dividend. Sustainability and ESG3.5 / 5Environmental Score-1.99 Short InterestThere is no current short interest data available for PKI. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for PKI on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Revvity insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.52% of the stock of Revvity is held by insiders.Percentage Held by Institutions85.22% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revvity's insider trading history. Receive PKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter. Email Address PKI Stock News HeadlinesRevvity Ramps Up R&D Spending Since PerkinElmer SplitOctober 15, 2024 | msn.comRevvity, Inc. (RVTY)July 19, 2024 | finance.yahoo.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.October 31, 2024 | Crypto Swap Profits (Ad)Revvity Inc PKIFebruary 13, 2024 | morningstar.comRevvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCIDDecember 1, 2023 | businesswire.comRevvity Stock (NYSE:RVTY), Analyst Ratings, Price Targets, PredictionsNovember 1, 2023 | benzinga.comRevvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis SolutionsOctober 29, 2023 | finance.yahoo.comRevvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS ViewAugust 2, 2023 | finance.yahoo.comSee More Headlines PKI Stock Analysis - Frequently Asked Questions How were Revvity's earnings last quarter? Revvity, Inc. (NYSE:PKI) posted its earnings results on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%. Is Revvity doing a stock buyback? Revvity's Board of Directors approved a stock buyback plan on Thursday, May 11th 2023, which permits the company to repurchase $600,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 4.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued. Does Revvity have any subsidiaries? The following companies are subsidiaries of Revvity: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and more. What other stocks do shareholders of Revvity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/11/2023Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:PKI CUSIP71404610 CIK31791 Webwww.perkinelmer.com Phone(781) 663-6900Fax781-663-5985Employees16,700Year Founded1937Price Target and Rating Average Stock Price Target$54.00 High Stock Price Target$54.00 Low Stock Price Target$54.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$7.68 Trailing P/E Ratio15.01 Forward P/E RatioN/A P/E Growth0.5Net Income$569.18 million Net Margins28.94% Pretax Margin13.81% Return on Equity11.17% Return on Assets5.83% Debt Debt-to-Equity Ratio0.48 Current Ratio2.43 Quick Ratio2.15 Sales & Book Value Annual Sales$3.31 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.88 Book Value$58.49 per share Price / BookN/AMiscellaneous Outstanding Shares126,410,000Free Float125,755,000Market Cap$14.57 billion OptionableOptionable Beta1.10 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:PKI) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.